• Recently, Leerink initiated coverage on Absci Corporation, emphasizing its AI-native, clinical-stage biologics pipeline, including lead candidate ABS-20 in Phase 1/2 and pipeline asset ABS-201 for alopecia and endometriosis, while MindWalk’s CEO joined Absci and a major AI compute provider on a Jones AI Day panel about AI-enabled drug discovery.
• Together, the supportive research coverage and Absci’s participation in a high-profile discussion on combining AI, biological context, and high-performance compute spotlight how the company’s platform and clinical programs are gaining attention across both capital markets and the AI drug discovery ecosystem.
• We’ll now explore how Leerink’s focus on Absci’s AI-driven clinical pipeline and upcoming data milestones may influence its broader investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.

Absci Investment Narrative Recap

To own Absci, you need to believe its AI-native platform can turn ABS-201 into clinically validated therapies for androgenetic alopecia and endometriosis, while the company manages ongoing losses and a limited cash runway. The key near term catalyst is early ABS-201 clinical data in 2026 and 2027, and Leerink’s new coverage plus the Jones AI Day panel raise visibility but do not materially change the core risk that early human data could disappoint.

Leerink’s initiation, highlighting ABS-20 in Phase 1/2 and framing 2026 as “data rich” for ABS-201, is most relevant here. It underscores that upcoming ABS-201 readouts remain central to the story, even as Absci’s broader AI-enabled pipeline and partnerships with major compute providers and biopharma peers are starting to attract more market attention.

Yet while interest is building, the risk that prolonged losses and a short cash runway may force less favorable financing is something investors should be aware of...

Absci's narrative projects $58.7 million revenue and $9.4 million earnings by 2028. This requires 175.3% yearly revenue growth and a $124.0 million earnings increase from $-114.6 million today.

Uncover how Absci's forecasts yield a $8.11 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could reach about US$151.2 million by 2028, but this AI Day spotlight and Leerink’s focus might push both those bullish expectations and more cautious views to shift as ABS-201 data and funding needs become clearer.

Explore 5 other fair value estimates on Absci - why the stock might be worth as much as 37% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Absci research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.
• Our free Absci research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Absci's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• Find 44 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.